November 14, 2025 Sweden
On the World Diabetes Day, November 14, Diamyd Medical hosted an expert panel on the future of type 1 diabetes treatment. The discussion explored: - How close the field is to modifying the course of type 1 diabetes rather than only managing its symptoms
- The impact of preserving endogenous insulin production on long-term stability and quality of life
- The convergence of immune tolerance and precision medicine in therapies such as Diamyd Medical’s GAD65-based approach
- How insights from earlier GAD studies are shaping the ongoing Phase 3 trial, with results expected around March 2026
Panel participants - Prof. Johnny Ludvigsson – pediatrician and T1D researcher, founder of Barndiabetesfonden and principal investigator in GAD/Diamyd® trials.
- Joshua Vieth, Breakthrough T1D – leads research strategy at a global T1D non-profit funding disease-modifying trials, including prevention.
- Prof. Åke Lernmark – T1D researcher focused on genetics, HLA and autoantibodies, central to understanding risk and prevention of the disease.
- Ulf Hannelius, CEO, Diamyd Medical. Diamyd Medical is developing a GAD65-based precision therapy (Diamyd®) to preserve the body’s own insulin production.
The webcast was produced by BioStock and moderated by Jonas Söderström.
|
November 3, 2025 USA
Ventures Accelerated summarizes how the 2025 Nobel Prize in Physiology or Medicine, awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for discoveries in peripheral immune tolerance, is now paving the way for new treatments for autoimmune and inflammatory diseases.
Through an interview with Nobel laureate Fred Ramsdell and examples from companies including Diamyd Medical, the article illustrates how decades of T-cell research are being translated into precision therapies and new investment opportunities in chronic inflammation and autoimmunity. The article also features Karin Rosén, a member of the board of directors of Diamyd Medical, who provides the company’s perspective on how these scientific breakthroughs connect to the development of antigen-specific treatments for type 1 diabetes. Read the article here
|
October 28, 2025 USA
BioStock recaps the Breakthrough T1D Mission Summit held in Miami on October 25–27, where leading researchers, clinicians, and industry voices discussed scientific progress and disease-modifying strategies that could change the course of type 1 diabetes. Anton Lindqvist, Chief Scientific Officer at Diamyd Medical, participated in the summit, contributing to discussions on emerging strategies to preserve insulin production. The discussion centered on preserving endogenous insulin production and accelerating therapies that improve long-term outcomes for people with T1D.
Read the article here
|
October 10, 2025 Sweden
BioStock summerar konferensen Framtidens screening, som hölls i Stockholm den 9 oktober. Evenemanget, som arrangerades av den Vinnova-finansierade innovationsmiljön ASSET tillsammans med DiaUnion och Sanofi, samlade forskare, vårdens aktörer och läkemedelsbolag för att diskutera hur nationell screening och förebyggande behandling av typ 1-diabetes kan bli verklighet i svensk hälso- och sjukvård. ASSET är ett partnerprojekt finansierat av Vinnova, där Diamyd Medical, MainlyAI, Leading Health Care Foundation, Svenska Nationella Diabetesregistret, Lunds universitet, Sahlgrenska Universitetssjukhuset och Örebro Universitetssjukhus samarbetar för att utveckla innovativa lösningar för precisionshälsa och digital vård. Läs artikeln här
|
October 8, 2025 Sweden
Diamyd Medical´s vd Ulf Hannelius presenterar bolagets Bokslutskommuniké och nuvarande status i bolaget.
Rapporten publicerades den 8 oktober 2025. Producerat i samarbete med BioStock, moderator Cecilia Hallström.
|